Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
NovaBay Pharmaceuticals, Inc is a biotechnology business based in the US. NovaBay Pharmaceuticals shares (NBY) are listed on the NYSE MKT and all prices are listed in US Dollars. NovaBay Pharmaceuticals employs 26 staff and has a trailing 12-month revenue of around USD$9.8 million.
|Latest market close||USD$0.58|
|52-week range||USD$0.24 - USD$1.64|
|50-day moving average||USD$0.6651|
|200-day moving average||USD$0.9063|
|Wall St. target price||USD$2.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.584|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||0.58|
|1 month (2020-10-23)||-19.99%|
|3 months (2020-08-25)||-36.26%|
|6 months (2020-05-23)||N/A|
|1 year (2019-11-25)||2.64%|
|2 years (2018-11-23)||-51.88%|
|3 years (2017-11-24)||-86.97%|
|5 years (2015-11-25)||286.92%|
|Revenue TTM||USD$9.8 million|
|Gross profit TTM||USD$4.9 million|
|Return on assets TTM||-26.72%|
|Return on equity TTM||-137.69%|
|Market capitalisation||USD$26.1 million|
TTM: trailing 12 months
There are currently 967,946 NovaBay Pharmaceuticals shares held short by investors – that's known as NovaBay Pharmaceuticals's "short interest". This figure is 143.5% up from 397,451 last month.
There are a few different ways that this level of interest in shorting NovaBay Pharmaceuticals shares can be evaluated.
NovaBay Pharmaceuticals's "short interest ratio" (SIR) is the quantity of NovaBay Pharmaceuticals shares currently shorted divided by the average quantity of NovaBay Pharmaceuticals shares traded daily (recently around 1.5 million). NovaBay Pharmaceuticals's SIR currently stands at 0.63. In other words for every 100,000 NovaBay Pharmaceuticals shares traded daily on the market, roughly 630 shares are currently held short.
However NovaBay Pharmaceuticals's short interest can also be evaluated against the total number of NovaBay Pharmaceuticals shares, or, against the total number of tradable NovaBay Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NovaBay Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 NovaBay Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.031% of the tradable shares (for every 100,000 tradable NovaBay Pharmaceuticals shares, roughly 31 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NovaBay Pharmaceuticals.
Find out more about how you can short NovaBay Pharmaceuticals stock.
We're not expecting NovaBay Pharmaceuticals to pay a dividend over the next 12 months.
NovaBay Pharmaceuticals's shares were split on a 1:25 basis on 21 December 2015. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NovaBay Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for NovaBay Pharmaceuticals shares which in turn could have impacted NovaBay Pharmaceuticals's share price.
Over the last 12 months, NovaBay Pharmaceuticals's shares have ranged in value from as little as $0.24 up to $1.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while NovaBay Pharmaceuticals's is 3.9814. This would suggest that NovaBay Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.